TWO · 6810.TWO
Bio Preventive Medicine Corp.
NT$22.55-NT$0.35 (-1.53%)
Bio Preventive Medicine Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
Loading market information…
TWO · 3118.TWO · TWD
Stock price, dividends
Quote as of Oct 30, 2026, 04:09 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Level Biotechnology Inc.’s quoted price sits in the lower half of its reported 52-week range, 11.82% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Level Biotechnology Inc.’s forward annual dividend is NT$2.20 per share, paid annual. The forward yield is 7.19% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immunology, and molecular biology, alongside advanced biomedical instrumentation, throughout Taiwan. Beyond product distribution, Level Biotechnology offers a comprehensive suite of research and testing services. These include expert assessments in mammalian and genetic toxicology, pharmacological studies, biocompatibility testing, and the production of model animals. The firm's preclinical research capabilities serve a diverse range of clients in the biotechnology, pharmaceutical, medical device, animal health, and agrichemical industries.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$22.55-NT$0.35 (-1.53%)
Bio Preventive Medicine Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
NT$23.00NT$0.00 (0.0%)
LabTurbo Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.88% below the high.
NT$13.80-NT$0.20 (-1.43%)
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
NT$13.95-NT$0.05 (-0.36%)
LAUNXP Biomedical Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 45.19% below the high.
NT$36.00NT$0.00 (0.0%)
TCI GENE Inc.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$18.70+NT$0.20 (+1.08%)
Lukas Biomedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.46% below the high.
NT$15.50NT$0.00 (0.0%)
NatureWise Biotech & Medicals Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.99% below the high.
NT$28.35NT$0.00 (0.0%)
BioLASCO Taiwan Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.5% below the high.
